The receipt of an $11.14 million milestone payment is a significant financial event for Cidara Therapeutics, indicating the company's ability to meet important regulatory milestones. This approval in Europe not only opens up new revenue streams but also validates the company's research and development capabilities. Such achievements are likely to be viewed positively by investors, potentially leading to a short-term increase in stock price due to increased investor confidence and the anticipated impact on future revenues.